



## Correction to: SEOM clinical guidelines for anaemia treatment in cancer patients (2020)

Y. Escobar Álvarez<sup>1</sup> · R. de las Peñas Bataller<sup>2</sup> · J. Perez Alrozano<sup>3</sup> · S. Ros Martínez<sup>4</sup> · A. Sabino Álvarez<sup>5</sup> · A. Blasco Cordellat<sup>6</sup> · E. Brozos Vázquez<sup>7</sup> · J. Corral Jaime<sup>8</sup> · I. García Escobar<sup>9</sup> · C. Beato Zambrano<sup>10</sup>

Published online: 21 July 2021  
© Federación de Sociedades Españolas de Oncología (FESEO) 2021

**Correction to: Clinical and Translational Oncology**  
<https://doi.org/10.1007/s12094-021-02580-2>

In Table 4 of this article, there were few mistakes and the corrected Table 4 is given below.

The original article can be found online at <https://doi.org/10.1007/s12094-021-02580-2>.

Y. Escobar Álvarez  
yolandaesco@yahoo.es

R. de las Peñas Bataller  
ramon.delaspesas@hospitalprovincial.es

J. Perez Alrozano  
jpalrozano@hotmail.com

S. Ros Martínez  
silveriorosmartinez@gmail.com

A. Sabino Álvarez  
arasabino@hotmail.com

A. Blasco Cordellat  
blascocordellat@yahoo.es

E. Brozos Vázquez  
elenambrozosv@hotmail.com

J. Corral Jaime  
jesuscorraljaime@hotmail.com

I. García Escobar  
naxto@hotmail.com

C. Beato Zambrano  
cbeatoz@hotmail.com

<sup>1</sup> Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

<sup>2</sup> Department of Medical Oncology, Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Spain

<sup>3</sup> Department of Medical Oncology, Hospital Virgen de Los Lirios, Alcoy, Spain

<sup>4</sup> Department of Medical Oncology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain

<sup>5</sup> Department of Medical Oncology, Hospital Universitario Puerta del Mar, Cádiz, Spain

<sup>6</sup> Department of Medical Oncology, Consorcio Hospital General Universitario, Valencia, Spain

<sup>7</sup> Department of Medical Oncology, Hospital Clínico Universitario de Santiago, la Coruña, Spain

<sup>8</sup> Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain

<sup>9</sup> Present Address: Hospital General Universitario Virgen de las Nieves, Granada, Spain

<sup>10</sup> Department of Medical Oncology, Hospital Universitario de Jerez de la Frontera, Cádiz, Spain

**Table 4** Iron compounds and approved dosages in patients with solid tumors and haematologic malignancies

Compound	Iron sucrose	Low molecular weight dextran iron	Ferric carboxymaltose
Test dose	Medical judgement, depending on the risk of reaction	Slow infusion of 25 mg over 15 min	Medical judgement, depending on the risk of reaction
Dosage	Dose: 200 mg IV in 100 mL sodium chloride 0.9% over 30–60 min (not more than 3 times per week) or 200 mg IV over 10 min, 5 times in 14 days. Total dose = 1000 mg	100–200 mg IV over 30 min Repeat dosing once a week for 10 doses for a total of 1000 mg or Full dose infusion over 4–6 h (total dose calculated in 500 mL 0.9% NaCl solution at 175 mL/h)	Hb < 10 g/dL in patients 35 to < 70 kg 1500 mg IV; in patients ≥ 70 kg 2000 mg IV Hb > 10 g/dL in patients 35 to < 70 kg 1000 mg IV; in patients ≥ 70 kg 1500 mg IV A maximum single dose of 20 mg/kg body weight (intravenous drip infusion) or 15 mg/kg body weight (intravenous injection) up to 1000 mg of iron can be administered. Administration time: 15 min. Do not administer 1000 mg of iron more than once per week

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.